Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

Please amend the claims as follows:

1. (currently amended) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula:

and physiologically acceptable salts thereof, wherein:

X is a hydrophobic aliphatic hydrocarbon chain containing from about 4 to about 30 carbon atoms and having one or more nonconjugated cis double bonds in the middle portion of the chain;

Y is selected from the group consisting of amide and ester radicals; and

Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl forming a ring with the Y group amide radical, aryl, hydroxy substituted aryl, heterocyclic, hydroxy substituted heterocyclic, a non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amido nitrogen forming part of the ring structure or a hydroxy substituted non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amido nitrogen forming part of the ring structure; with the proviso that,

if X contains from 18 to 21 carbon atoms and Y is an amide radical, then Z cannot be hydrogen.

- 2. (original) The method of claim 1 wherein Z is a polar nonionizable group containing a hydroxy moiety at its distal end.
- 3. (original) The method of claim 1 wherein Y is an amide radical.
- 4. (withdrawn) The method of claim 1 wherein Y is an ester radical.

Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

5. (original) The method of claim 1 wherein X has two or more nonconjugated double bonds.

6. (original) The method of claim 1 wherein X has at least four nonconjugated double bonds.

7. (withdrawn) The method of claim 1 wherein Z is a hydroxy substituted anyl group.

8. (withdrawn) The method of claim 1 wherein Z includes an alkyl group alpha to the amido nitrogen.

9. (withdrawn) The method of claim 1 wherein Z is an (S) isomer of a chiral molecule.

10-11. (canceled)

12-20. (canceled)

21. (previously presented) The method of claim 1 wherein X is a hydrophobic aliphatic hydrocarbon chain containing 19 carbon atoms and having 4 nonconjugated cis double bonds in the middle portion of the chain and Y is an amide radical.

22. (canceled)

23. (currently amended) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula[[:]]

Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

$$X-Y-Z$$

and physiologically acceptable salts thereof, wherein:

X is a hydrophobic aliphatic hydrocarbon chain containing from about 4 to about 30 carbon atoms and having one or more nonconjugated cis double bonds in the middle portion of the chain;

Y is selected from the group consisting of amide and ester radicals; and

Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl, hydroxy substituted lower alkyl forming a ring with the Y group amide radical, aryl, hydroxy substituted aryl, a non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amide nitrogen forming part of the ring structure or a hydroxy substituted non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amide nitrogen forming part of the ring structure; with the provise that,

if X contains from 18 to 21 carbon atoms and Y is an amide radical, then Z cannot be hydrogen; and

if X is an arachidonic acid radical and Y is an amide radical than Z cannot be selected from the group consisting of 3- hydroxyphenyl or 4-hydroxyphenyl selected from:

Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

$$AA - C - NH - C_2H_5, \quad AA - C - NH \rightarrow OH$$

$$AA - C - O - C_4H_2OH$$

$$AA - C - O \rightarrow OH$$

$$AA - C - N \rightarrow OH$$

Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

24. (new) The method of claim 23 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

$$AA - C - NH - C_2H_5, \quad AA - C - NH \longrightarrow OH, \quad AA - C - O - C_4H_2OH$$

$$AA - C - O - C \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N \longrightarrow OH \qquad AA - C - N \longrightarrow OH$$

$$AA - C - N$$

25. (new) The method of claim 23 wherein the compound is represented by the following structural formula and physiologically acceptable salts thereof:

Response to Office communication dated: 8/25/2004

Attorney Docket: UCONAP/141/US

26. (new) The method of claim 1 wherein:

X is AA; Y is an amide radical; and Z is selected from the group consisting of hydrogen, lower alkyl, hydroxy substituted lower alkyl, hydroxy substituted lower alkyl forming a ring with the Y group amide radical, aryl, hydroxy substituted aryl, heterocyclic, hydroxy substituted heterocyclic, a non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amido nitrogen forming part of the ring structure or a hydroxy substituted non-aromatic ring system of 4 to 8 carbon atoms containing one or more heteroatoms such as oxygen or nitrogen with the Y moiety amido nitrogen forming part of the ring structure; with the proviso that Z cannot be selected from the group consisting of 3-hydroxyphenyl or 4-hydroxyphenyl.

27. (new) A method of inhibiting transport of anandamide in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound represented by the following structural formula and physiologically acceptable salts thereof: